Table 2. Control group (delayed-start canagliflozin group).

Visit	Observation period
	Before starting	Week 0	Week 12(month 3)	Week 24(month 6)	Week 36(month 9)	Week 48(month 12)	Week 76(month 18)
Schedule window	–	–	±6 week	±9 week	±12 week	±12 week	±12 week
Informed consent	X
Enrolment	X
Allocation	X
Patient characteristics	X
Physical examination	X	X	X	X	X	X	X
Blood test		X	X	X	X	X	X
Plasma BNP		X	X	X	X	X	X
Image tests*		X		X		X	X
Kt/Vurea, PET†		X		X		X	X
Use of concomitant drugs
Adverse events

^*Image tests; CT scan, cardiac echo, cervical echo, Holter ECG, chest X-ray and bone mineral density measurement at week 0 should be performed from 12 weeks prior to the start of observation to week 0.

^†Kt/Vurea, PET; week 0 should be performed 24 weeks prior to the start of administration to 0 week. Week 48 is not required.

BNPbrain natriuretic peptidePETperitoneal equilibration test